The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-30), Mustang Bio's share price is $0.237. Mustang Bio's Book Value per Share for the quarter that ended in Dec. 2023 was $0.01. Hence, Mustang Bio's PB Ratio of today is 18.23.
Warning Sign:
Mustang Bio Inc stock PB Ratio (=24.32) is close to 10-year high of 24.32
The historical rank and industry rank for Mustang Bio's PB Ratio or its related term are showing as below:
MBIO'
s PB Ratio Range Over the Past 10 Years
Min: 0.01 Med: 1.69 Max: 32.65
Current: 23.7
During the past 9 years, Mustang Bio's highest PB Ratio was 32.65. The lowest was 0.01. And the median was 1.69.
MBIO's PB Ratio is ranked worse than 96.41% of 1308
companies
in the Biotechnology industry
Industry Median: 2.435
vs MBIO: 23.70
During the past 12 months, Mustang Bio's average Book Value Per Share Growth Rate was -99.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -91.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -68.20% per year.
During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of Mustang Bio was 11.50% per year. The lowest was -91.40% per year. And the median was -15.60% per year.
Back to Basics: PB Ratio
Mustang Bio PB Ratio Historical Data
The historical data trend for Mustang Bio's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Mustang Bio's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mustang Bio's PB Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Mustang Bio's PB Ratio distribution charts can be found below:
* The bar in red indicates where Mustang Bio's PB Ratio falls into.
Mustang Bio PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Mustang Bio's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Mustang Bio PB Ratio Related Terms
Thank you for viewing the detailed overview of Mustang Bio's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies and CAR T therapies for solid tumors.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MBIO has been successfully added to your 